Loading clinical trials...
Loading clinical trials...
WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2. A Prospective, Multicenter, Randomized, Active Controlled, Clinical Trial of the Coherex WaveCrest® Left Atrial Appendage Occlusion System Compared to the Watchman® LAA Closure Device for the Reduction in Risk of Ischemic Stroke or Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation That Have an Appropriate Rationale to Seek a Non-pharmacologic Alternative to Chronic Oral Anticoagulation.
Conditions
Interventions
Coherex WaveCrest® Left Atrial Appendage Occlusion System
Watchman® LAA Closure Device
Locations
25
United States
Grandview Medical Center
Birmingham, Alabama, United States
Dignity Health Mercy Gilbert Medical Center
Chandler, Arizona, United States
Pacific Heart Institute / St. John's Health Center
Los Angeles, California, United States
Medstar Heart and Vascular Institute - Washington Hospital Center
Washington D.C., District of Columbia, United States
St. Vincent's Medical Center
Jacksonville, Florida, United States
Piedmont Heart Institute
Atlanta, Georgia, United States
Start Date
December 27, 2017
Primary Completion Date
December 21, 2023
Completion Date
December 21, 2023
Last Updated
March 12, 2025
NCT05093673
NCT06258538
NCT07371455
NCT06870812
NCT07253181
NCT05147792
Lead Sponsor
Coherex Medical
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions